First Patient Dosed in Phase 1/ 2 Clinical Study of Novel EGFR/ HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/ DB-1418
Veröffentlicht: 07.08.2025 um 18:08 Uhr, prnewswire.co.uk
View original content:https://www.prnewswire.co.uk/news-releases/first-patient-dosed-in-phase-12-clinical-study-of-novel-egfrher3-bispecific-antibody-drug-conjugate-avzo-1418db-1418-302500893.html
en | boerse | 67929135 |
